Metastatic Hormone Refractory Prostate Cancer Enrolling by Invitation Phase 2 Trials for Abiraterone (DB05812)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Enrolling by Invitation2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02962284One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™Treatment